Latest Rewards And Loyalty News

Klevo Rewards is pursuing an Australian Credit Licence acquisition to enable crypto-centric credit products for Fly Wallet users, aiming to reduce declined transactions and boost platform utility.

Critical Resources Limited (ASX:CRR) has initiated a pro-rata entitlement offer of Loyalty Options priced at $0.001 each, aiming to raise $319,410 and potentially $2.56 million upon exercise. The offer underscores significant dilution and operational risks amid ongoing exploration and legal challenges.

Xenitra Limited (ASX:XEN) has introduced the OPAL Token and Xen Shop, a blockchain-based digital commerce ecosystem aimed at improving product authentication, customer loyalty, and sales transparency across its Asian FMCG markets.

Desert Metals Limited (ASX:DM1) has announced a pro-rata 1-for-2 non-renounceable entitlement offer of up to 325 million new options to raise approximately $325,377. The funds will support ongoing aircore drilling at its Tiogo and Kakalogo gold prospects in Côte d’Ivoire.

Klevo Rewards Limited’s subsidiary Fly Wallet has secured key Mastercard compliance and earned over AUD 550,000 in incentives, marking a significant step in its payments platform evolution.

AdNeo Limited’s subsidiary Learnt has landed a significant 12-month contract with Hisense Australia to deliver a comprehensive corporate learning and loyalty platform, marking a strategic expansion in the enterprise learning market.

Jindalee Lithium has successfully raised $1.5 million through an oversubscribed Share Purchase Plan, exceeding its $1 million target to fund the McDermitt Lithium Project and a US SPAC transaction.

Algorae Pharmaceuticals has launched a Loyalty Options Offer, allowing eligible shareholders to purchase options at a nominal price, aiming to reward loyalty and support future growth funding.

ECS Botanics has successfully raised nearly A$2 million through a placement aimed at accelerating its international expansion and product development. The move underscores growing investor confidence in the medicinal cannabis company’s strategic growth plans.

Gratifii Limited reported a remarkable 106% increase in cash receipts for 1Q FY26 despite seasonal and weather challenges, while nearing completion of its major platform integration.

My Rewards International Limited reports a 47% revenue drop but narrows losses by 45%, fueled by strategic acquisition and tech innovation. The company advances ASX reinstatement with a capital raise and debt conversion plan.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.